News releases from Eli Lilly and Company
Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes
May 06, 2021
Partners offer app compatibility with Tempo Pen™ and Tempo Smart Button™ to help streamline diabetes management through automated data collection for insulin dose tracking
Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2021 Health Care Conference on Tuesday, May 11, 2021. Michael Mason, senior vice president, president of Lilly...
Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries
May 04, 2021
- Environmental, Social and Governance (ESG) goals focus on key topics including access and affordability, diversity and inclusion, racial justice and the environment
Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements
May 04, 2021
- Lilly is working with the Indian government to provide baricitinib donations in conjunction with the permission
Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization
May 03, 2021
The board of directors of Eli Lilly and Company (NYSE: LLY) (the "Board") has declared a dividend for the second quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable...
OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses
April 23, 2021
- Extended safety analysis across eight studies helps further define the known safety profile of OLUMIANT 2-mg in atopic dermatitis -
Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis
April 23, 2021
- Results from first network meta-analysis based on area under the curve of 52-week clinical trial data -
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
April 20, 2021
- Results from two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth across both baricitinib dosing groups, compared to placebo
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
April 16, 2021
- Final step in Lilly's planned transition to provide only bamlanivimab and etesevimab together in the U.S.
Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer
April 13, 2021
Eli Lilly and Company (NYSE: LLY) announced today that Diogo Rau will join the company on May 17, 2021 as senior vice-president and chief information and digital officer. Rau succeeds Aarti Shah, whose...
Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together
April 12, 2021
Eli Lilly and Company (NYSE: LLY) today announced changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for...
Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting
April 11, 2021
Confirmed Objective Response Rate of 47 Percent, with Responses Observed in Nine Unique Cancer Types
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
April 08, 2021
- Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical...
Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement
April 06, 2021
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021. Lilly will also conduct a conference call on that day with the investment community...
Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts
April 01, 2021
Eli Lilly and Company (NYSE: LLY) will host a webcast for the investment community, media and the general public on May 4, 2021 to provide an overview of the company's strong commitment to...
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
March 31, 2021
- More than 80 percent of HCPs wish they had the time to more closely track patients who are seeing multiple providers
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
March 29, 2021
- In combination, the two monoclonal antibodies demonstrated a 70% relative reduction in persistently high viral load at day 7 compared to placebo -
Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021
March 17, 2021
PRO data further support the monarchE results to date for Verzenio for the treatment of HR+, HER2- high risk early breast cancer
Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
March 16, 2021
- Patients treated with mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints compared to placebo
Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
March 13, 2021
Findings from the primary endpoint supported by consistency of all secondary outcome measures assessing cognition and function
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)
March 10, 2021
Presentation of Phase 1/2 LIBRETTO-001 trial data will highlight safety and efficacy data of Retevmo® (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
March 10, 2021
Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research
March 09, 2021
Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations
March 09, 2021
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes
March 08, 2021
Biolojic is eligible to receive up to $121 million, consisting of potential milestones and a promissory note, as well as tiered royalties
Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021. Patrik Jonsson, senior vice president, president of Lilly USA and chief...
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
March 05, 2021
CHMP has completed a review of available data for both antibodies for the treatment of confirmed COVID-19